File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: Progression-free survival analysis of a phase III randomized trial

TitleConcurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: Progression-free survival analysis of a phase III randomized trial
Authors
Issue Date2002
Citation
Journal of Clinical Oncology, 2002, v. 20, n. 8, p. 2038-2044 How to Cite?
AbstractPurpose: Nasopharyngeal carcinoma (NPC) is highly sensitive to both radiotherapy (RT) and chemotherapy. This randomized phase III trial compared concurrent cisplatin-RT (CRT) with RT alone in patients with locoregionally advanced NPC. Patients and Methods: Patients with Ho's N2 or N3 stage or N1 stage with nodal size ≥ 4 cm were randomized to receive cisplatin 40 mg/m 2 weekly up to 8 weeks concurrently with radical RT (CRT) or RT alone. The primary end point was progression-free survival (PFS). Results: Three hundred fifty eligible patients were randomized. Baseline patient characteristics were comparable in both arms. There were significantly more toxicities, including mucositis, myelosuppression, and weight loss in the CRT arm. There were no treatmentrelated deaths in the CRT arm, and one patient died during treatment in the RT-alone arm. At a median follow-up of 2.71 years, the 2-year PFS was 76% in the CRT arm and 69% in the RT-alone arm (P = .10) with a hazards ratio of 1.367 (95% confidence interval [CI], 0.93 to 2.00). The treatment effect had a significant covariate interaction with tumor stage, and a subgroup analysis demonstrated a highly significant difference in favor of the CRT arm in Ho's stage T3 (P = .0075) with a hazards ratio of 2.328 (95% CI, 1.26 to 4.28). For T3 stage, the time to first distant failure was statistically significantly different in favor of the CRT arm (P= .016). Conclusion: Concurrent CRT is well tolerated in patients with advanced NPC in endemic areas. Although PFS was not significantly different between the concurrent CRT arm and the RT-alone arm in the overall comparison, PFS was significantly prolonged in patients with advanced tumor and node stages. © 2002 by American Society of Clinical Oncology.
Persistent Identifierhttp://hdl.handle.net/10722/251600
ISSN
2020 Impact Factor: 44.544
2015 SCImago Journal Rankings: 9.204
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChan, A. T.C.-
dc.contributor.authorTeo, P. M.L.-
dc.contributor.authorNgan, R. K.-
dc.contributor.authorLeung, T. W.-
dc.contributor.authorLau, W. H.-
dc.contributor.authorZee, B.-
dc.contributor.authorLeung, S. F.-
dc.contributor.authorCheung, F. Y.-
dc.contributor.authorYeo, W.-
dc.contributor.authorYiu, H. H.-
dc.contributor.authorYu, K. H.-
dc.contributor.authorChiu, K. W.-
dc.contributor.authorChan, D. T.-
dc.contributor.authorMok, T.-
dc.contributor.authorYuen, K. T.-
dc.contributor.authorMo, F.-
dc.contributor.authorLai, M.-
dc.contributor.authorKwan, W. H.-
dc.contributor.authorChoi, P.-
dc.contributor.authorJohnson, P. J.-
dc.date.accessioned2018-03-08T05:00:26Z-
dc.date.available2018-03-08T05:00:26Z-
dc.date.issued2002-
dc.identifier.citationJournal of Clinical Oncology, 2002, v. 20, n. 8, p. 2038-2044-
dc.identifier.issn0732-183X-
dc.identifier.urihttp://hdl.handle.net/10722/251600-
dc.description.abstractPurpose: Nasopharyngeal carcinoma (NPC) is highly sensitive to both radiotherapy (RT) and chemotherapy. This randomized phase III trial compared concurrent cisplatin-RT (CRT) with RT alone in patients with locoregionally advanced NPC. Patients and Methods: Patients with Ho's N2 or N3 stage or N1 stage with nodal size ≥ 4 cm were randomized to receive cisplatin 40 mg/m 2 weekly up to 8 weeks concurrently with radical RT (CRT) or RT alone. The primary end point was progression-free survival (PFS). Results: Three hundred fifty eligible patients were randomized. Baseline patient characteristics were comparable in both arms. There were significantly more toxicities, including mucositis, myelosuppression, and weight loss in the CRT arm. There were no treatmentrelated deaths in the CRT arm, and one patient died during treatment in the RT-alone arm. At a median follow-up of 2.71 years, the 2-year PFS was 76% in the CRT arm and 69% in the RT-alone arm (P = .10) with a hazards ratio of 1.367 (95% confidence interval [CI], 0.93 to 2.00). The treatment effect had a significant covariate interaction with tumor stage, and a subgroup analysis demonstrated a highly significant difference in favor of the CRT arm in Ho's stage T3 (P = .0075) with a hazards ratio of 2.328 (95% CI, 1.26 to 4.28). For T3 stage, the time to first distant failure was statistically significantly different in favor of the CRT arm (P= .016). Conclusion: Concurrent CRT is well tolerated in patients with advanced NPC in endemic areas. Although PFS was not significantly different between the concurrent CRT arm and the RT-alone arm in the overall comparison, PFS was significantly prolonged in patients with advanced tumor and node stages. © 2002 by American Society of Clinical Oncology.-
dc.languageeng-
dc.relation.ispartofJournal of Clinical Oncology-
dc.titleConcurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: Progression-free survival analysis of a phase III randomized trial-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1200/JCO.2002.08.149-
dc.identifier.pmid11956263-
dc.identifier.scopuseid_2-s2.0-0037089592-
dc.identifier.volume20-
dc.identifier.issue8-
dc.identifier.spage2038-
dc.identifier.epage2044-
dc.identifier.isiWOS:000175154900014-
dc.identifier.issnl0732-183X-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats